|
Teva's Reslizumab Shows Reduction In Asthma Exacerbations In Clinical Studies
RTT News Teva Pharmaceutical Industries Ltd. (TEVA: Quote) announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma … |
View full post on asthma – Google News